DEA Strips Oklahoma Doctor of Drug Prescription Rights
Published Date: 4/16/2025
Notice
Summary
Dr. Henry-Norbert O. Ndekwe from Oklahoma lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration, which expired on October 31, 2024. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA revokes registrations without state authority
Under 21 U.S.C. 824(a)(3), the DEA will revoke a practitioner's registration if the practitioner no longer has state authority to handle controlled substances. If your state license is suspended, revoked, or otherwise expired so you are not authorized to dispense controlled substances, you become ineligible to maintain a DEA registration and lose the legal right to prescribe or handle controlled drugs.
Dr. Ndekwe’s DEA registration revoked
The DEA revoked Henry-Norbert O. Ndekwe, M.D.'s Certificate of Registration No. BN5794587 and denied any pending applications to renew, modify, or obtain additional registration in Oklahoma. The agency noted his Oklahoma medical license expired on June 1, 2023, his DEA registration had expired on October 31, 2024, he did not request a hearing, and the Order is effective May 16, 2025. He may file a motion for reconsideration of the Agency's factual finding within fifteen calendar days to dispute the official notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06419, Optimize Growth Equity Fund, Optimize Premium Yield Fund and Optimize Wealth Management Inc.
Optimize Growth Equity Fund, Optimize Premium Yield Fund, and Optimize Wealth Management Inc. want permission to offer investors monthly chances to sell back their shares, instead of less often. This change could make it easier and quicker for investors to get their money when they want. The SEC will decide by May 6, 2025, unless someone asks for a hearing.
Next: 2025-06422, Agency Information Collection Activities: Proposed Request and Comment Request
The Social Security Administration wants your thoughts on their plan to keep and improve how people submit documents online using eSignatures and uploads. This update aims to make things easier and faster for everyone who deals with Social Security, with no new costs expected. You’ve got until June 16, 2025, to share your ideas and help shape the future of these digital services!